Leerink Partners' Rating of Rhythm Pharmaceuticals on 9/14/2026

On September 14, 2026, Leerink Partners updated its outlook on Rhythm Pharmaceuticals (NASDAQ:RYTM) with the action "Initiated Coverage", setting a "Outperform" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Leerink Partners

DateCompanyAction
11/17/2026
Erasca, Inc. stock logo
ERAS
Erasca
Initiated Coverage
11/17/2026
Viatris Inc. stock logo
VTRS
Viatris
Boost Price Target
11/16/2026
Benitec Biopharma Limited stock logo
BNTC
Benitec Biopharma
Boost Price Target
11/16/2026
Palvella Therapeutics, Inc. stock logo
PVLA
Palvella Therapeutics
Initiated Coverage
11/13/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Lower Price Target
11/13/2026
KARD
Kardigan
Lower Price Target
More Ratings From Leerink Partners